These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 33616256)

  • 1. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy.
    Sineshaw HM; Zettler CM; Prescott J; Garg M; Chakraborty S; Sarpong EM; Bai C; Belli AJ; Fernandes LL; Wang CK
    Cancer Med; 2024 Apr; 13(7):e7173. PubMed ID: 38597118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Gatwood J; Masaquel A; Fox D; Sheinson D; James C; Li J; Hossain F; Ross R
    J Med Econ; 2024; 27(1):738-745. PubMed ID: 38686393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
    Tsutsué S; Tobinai K; Yi J; Crawford B
    PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
    Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
    JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation.
    Acheampong T; Gu T; Le TK; Keating SJ
    Future Oncol; 2024 Mar; 20(10):623-634. PubMed ID: 38230990
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
    Ren J; Asche CV; Shou Y; Galaznik A
    J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
    Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
    Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
    Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
    Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
    Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
    Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
    Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark.
    Jakobsen LH; Øvlisen AK; Severinsen MT; Bæch J; Kragholm KH; Glimelius I; Gang AO; Jørgensen JM; Frederiksen H; Poulsen CB; Clausen MR; Pedersen PT; Pedersen RS; Torp-Pedersen C; Eloranta S; El-Galaly TC
    Blood Cancer J; 2022 Jan; 12(1):16. PubMed ID: 35087026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    J Med Econ; 2021; 24(1):469-478. PubMed ID: 33784916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study.
    Musimar Z; Mpetani M; Abramson JS; Chabner BA; Mohamed Z
    Oncologist; 2023 Sep; 28(9):e756-e764. PubMed ID: 37053476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
    Snider JT; McMorrow D; Song X; Diakun D; Wade SW; Cheng P
    Clin Ther; 2022 Apr; 44(4):521-538. PubMed ID: 35241295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
    Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
    Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.